Arch Biopartners Progresses with No Objection Letter from Health Canada
In a significant leap forward, Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) has announced that its prestigious clinical team has received a No Objection Letter (NOL) from Health Canada. This approval enables the initiation of the investigator-led clinical trial, named the Prevention Of Nephrotoxin Induced Acute Kidney Injury with Cilastatin (PONTiAK).
Overview of the PONTiAK Trial
The PONTiAK trial is set to involve 700 patients, a refined figure down from an initial estimate of 900. The trial aims to explore the potential of cilastatin in preventing acute kidney injury (AKI) linked to various drugs, such as certain antibiotics and chemotherapeutic agents.
Funding and Team Collaboration
The PONTiAK clinical team, operating from the prestigious Universities of Calgary and Alberta, has been awarded $1,500,000 in funds from the Canadian Institutes of Health Research (CIHR) to facilitate this trial. An additional $400,000 has been secured through the Accelerating Clinical Trials (ACT) initiative, which focuses on evaluating Canadian biotechnologies through randomized controlled trials. The allocation from both grants will support the clinical team in executing the trial across multiple hospital sites in Alberta.
Preparing for Trial Commencement
As preparations for the PONTiAK trial continue, the clinical team is currently setting up hospital sites and aims to secure necessary approvals from the local Research Ethics Board (REB) and the Alberta Health Services (AHS). Arch Biopartners is serving as a supportive partner in facilitating grant funding opportunities while also providing the cilastatin drug product essential for the trial’s success.
Exploring Opportunities Beyond the Trial
While the PONTiAK team works diligently to set operations in motion, Arch is actively seeking chances to sponsor an additional arm of the PONTiAK study in other jurisdictions, including the United States and Europe. This expansion could significantly amplify the impact of their research across a broader international audience.
Understanding Acute Kidney Injury
Acute kidney injury (AKI) represents a spectrum of clinical conditions, from mild to severe injuries that may result in permanent kidney damage. Common triggers include sepsis and exposure to various toxic agents, including drugs. Unfortunately, no specific treatment options currently exist to prevent AKI, leaving suffering patients in critical need of effective care solutions.
The Role of Drug Toxins in AKI
Drug-induced toxins account for about 30% of AKI cases occurring in inpatient settings. These can stem from a diverse array of pharmaceuticals, particularly antibiotics and chemotherapeutic agents. Alarmingly, AKI linked to cardiac surgeries also comprises up to 20% of hospital-acquired AKI incidences.
Cilastatin: A Promising Candidate
Cilastatin was originally developed by Merck Sharp & Dohme Research Laboratories in the 1980s to enhance the effectiveness of imipenem, a broad-spectrum antibiotic used for treating systemic infections. Approved in 1985, cilastatin has been utilized in conjunction with imipenem under different brand names globally. However, its standalone potential as a remedy for AKI has not been fully explored until now.
Distinct Mechanism of Action
Unlike Arch's leading drug candidate, the LSALT peptide (Metablok), which specifically targets inflammation through the inhibition of dipeptidase-1 (DPEP1), cilastatin possesses broader off-target effects. These effects allow cilastatin to ameliorate toxin influx in the kidneys. This unique property makes cilastatin particularly promising for addressing toxin-related acute kidney injury.
About Arch Biopartners Inc.
Arch Biopartners Inc. is dedicated to addressing acute kidney injury and related organ damage caused by inflammatory responses. The company is pioneering a series of innovative drug candidates aimed at inhibiting the DPEP1 pathway, with a strong emphasis on developing solutions to tackle unmet medical needs associated with renal injuries.
Commitment to Advancing Medical Science
Arch's primary candidates, cilastatin and the LSALT peptide, are being meticulously developed to address significant gaps in treatment for kidney injury induced by inflammation and drugs. To learn more about Arch Biopartners and their groundbreaking studies, further information can be directly accessed through their official channels.
Frequently Asked Questions
What is the PONTiAK trial about?
The PONTiAK trial evaluates the efficacy of cilastatin in preventing acute kidney injury induced by drug toxins.
How many patients will participate in the PONTiAK trial?
Initially planned for 900 participants, the trial will now involve 700 patients.
What is Arch Biopartners Inc. focused on?
Arch Biopartners specializes in clinical trials that aim to prevent acute kidney injury and other organ damage caused by inflammation.
What significant funding has PONTiAK received?
The PONTiAK trial has received funding from CIHR totaling $1.5 million and an additional $400,000 from ACT.
What distinguishes cilastatin from Arch's LSALT peptide?
Cilastatin prevents drug-related kidney toxicity through off-target effects, while LSALT peptide specifically mitigates inflammatory responses in the kidneys.
